| Description | GSK2636771, an effective, specific, orally bioavailable, PI3Kβ inhibitor, has been used in cancer, lymphoma, solid neoplasm, recurrent solid neoplasm, and advanced malignant neoplasm. |
| In vitro | 在小鼠中,GSK-2636771 （100 mg/kg）不增加葡萄糖/胰岛素水平.在移植瘤模型中,GSK-2636771降低磷酸化的蛋白激酶Akt（Ser473）水平. |
| In vivo | 在PTEN缺失细胞系中,GSK-2636771具有特异的抑制活性,在人前列腺癌PC-3（EC50=36 nM）和乳腺癌HCC70（EC50=72 nM）。 |
| Cell experiments | Cells are plated in 96-well microtiter plates at densities ranging from 1,500 to 15,000 cells/well, optimized for untreated control cells to be 80-90% confluent at the endpoint of the experiment. After 24 h, cells are treated with serial dilutions (100pM to 10μM) of GSK2636771. Cell viability is assessed after 72 h of treatment by incubation with CellTiter Blue for 1.5 h. The drug concentration requires for survival of 50% of cells relative to untreated cells (surviving fraction 50, SF50) is determined using GraphPad Prism version 5.0d. Cell lines that fails to achieve the SF50 to a given drug are nominally assigned as the highest concentration screened (i.e. 10μM). At least three independent experiments in triplicate per cell line targeted drug are performed. Association between a mutation and response to a targeted agent is determined using a Fisher’s exact test (GraphPad Prism), and a two-tailed P value <0.05 is considered statistically significant. (Only for Reference) |
| Target activity | PI3Kβ:5.2 nM |
| Synonyms | GSK 2636771, GSK-2636771 |
| molecular weight | 433.42 |
| Molecular formula | C22H22F3N3O3 |
| CAS | 1372540-25-4 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | H2O: < 1 mg/mL (insoluble or slightly soluble) Ethanol: < 1 mg/mL (insoluble or slightly soluble) DMSO: 9 mg/mL (20.77 mM), Sonication is recommended. |
| References | 1. Macauley D, et al. Drugs Fut, 2012, 37(6), 451. 2. Weigelt B, et al. Clin Cancer Res. 2013, 19(13), 3533-3544. |